Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy


About this study

The purpose of this study is to identify hereditary causes of cardiomyopathy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with a diagnosis of a non-MI SCA who survived
  • Patients with a non-MI SCD
  • Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected
  • Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)

Exclusion Criteria:

  • Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease
  • Significant coronary artery disease (Epicardial coronary artery stenosis >50%) which can explain degree of LV dysfunction
  • Those unwilling to provide written consent or assent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Virend Somers, M.D., Ph.D.

Open for enrollment

Contact information:

Nicholas Wozniak

(507) 255-8794

More information


Publications are currently not available

Mayo Clinic Footer